Verition Fund Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Verition Fund Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,884	Closed	-$259K	–	2360
2021 Q1	$259K	Buy	+6,884	New	+$172K	﹤0.01%	1192

Verition Fund Management's FPRX Position: Q2 2021 in Review

Verition Fund Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 6,884 shares — an estimated $259K sold.

Verition Fund Management first reported a position in FPRX in Q1 2021 and held it in 1 quarter. The position peaked at $259K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Verition Fund Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Verition Fund Management sold 6,884 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $259K.
Verition Fund Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
Verition Fund Management's Five Prime Therapeutics, Inc. position peaked at $259K in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Verition Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.